OR WAIT null SECS
May 09, 2023
Boehringer Ingelheim will use Ginkgo’s metagenomic sequence database to identify potential lead molecules for diseases with high unmet patient needs.
May 08, 2023
These models are useful in predicting whether an unknown substance of abuse can permeate the BBB to produce effects predicted by the Public Health Assessment via Structural Evaluation (PHASE) approach.
May 03, 2023
mRNA therapeutics are being researched to support the fight against rare diseases, infectious viruses, and cancers.
April 25, 2023
Aspect Biosystems and Novo Nordisk A/S have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics.
April 20, 2023
SAB Biotherapeutics has received both breakthrough and fast track designations from FDA for its lead antibody drug candidate for treating influenza.
April 18, 2023
Merck will acquire Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, at a total equity valuation of $10.8 billion.
Gamida Cell’s therapy is meant to reduce the risk of infection following stem cell transplantation.
April 14, 2023
FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.
Under this partnership, the two companies will develop bioprinted tissue therapeutics for diabetes and obesity.
April 07, 2023
If approved, Johnson & Johnson would pay $8.9 billion to resolve all current and future claims in its ongoing talc litigation.